CureVac N.V. (LON:0A9E)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 537.36M |
| Revenue (ttm) | 442.58M |
| Net Income (ttm) | 134.12M |
| Shares Out | n/a |
| EPS (ttm) | 0.60 |
| PE Ratio | 4.01 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 325 |
| Average Volume | 9,326 |
| Open | 3.210 |
| Previous Close | 3.100 |
| Day's Range | 3.090 - 3.155 |
| 52-Week Range | 1.780 - 4.218 |
| Beta | n/a |
| RSI | 58.50 |
| Earnings Date | Apr 25, 2025 |
About CureVac
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company’s portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In additi... [Read more]
News
CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript
CureVac BV reports Q4 results
CureVac N.V. 2024 Q4 - Results - Earnings Call Presentation
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update
Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate Transformation Completed enrollment of Part B of Phase 1 glioblastoma study with investigational precisi...
Earnings Scheduled For April 10, 2025
Companies Reporting Before The Bell • CureVac (NASDAQ: CVAC) is likely to report quarterly loss at $0.09 per share on revenue of $20.58 million. • CarMax (NYSE: KMX) is projected to report quarterly...
Insights Ahead: CureVac's Quarterly Earnings
CureVac (NASDAQ: CVAC) is set to give its latest quarterly earnings report on Thursday, 2025-04-10. Here's what investors need to know before the announcement. Analysts estimate that CureVac will rep...
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025
TÜBINGEN, DE / ACCESS Newswire / April 8, 2025 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid...
CureVac to initiate Phase 1 trial for its lung cancer therapy
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
Significant Regulatory Milestone: U.S. FDA cleared IND application for CVHNLC, CureVac's investigational therapy targeting squamous non-small cell lung cancer Proprietary Epitopes: CVHNLC encodes nove...
CureVac: Patent Win Notable, But Won't Answer More Fundamental Questions
CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit
Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech.
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps
CureVac N.V. (NASDAQ: CVAC) on Thursday said the European Patent Office (EPO) confirmed the validity of CureVac’s European patent EP 3 708 668 B1 subject to amendments to specify the scope of protect...
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps
CureVac N.V. CVAC on Thursday said the European Patent Office (EPO) confirmed the validity of CureVac's European patent EP 3 708 668 B1 subject to amendments to specify the scope of protection.
European Patent Office declares CureVac mRNA patent valid
The European Patent Office declared a patent owned by CureVac , valid, after a challenge from drugmaker BioNTech , the company said on Thursday.
CureVac up 13% as court upholds validity of patent in BioNTech spat
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended form A hearing on infringement of EP ...
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators
CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolio The company holds one of t...
Why CureVac (CVAC) Shares Are Volatile
CureVac BV (NASDAQ: CVAC) shares have been volatile over the past week, gaining some 25% to $4.23, amid increased trading volume following the U.S.’s first human death from H5N1 bird flu . What To Kn...
CureVac: Latest GBM Data Bodes Well For Next Program Check Point
CureVac recently released new clinical data. Why should investors care? Click here to find out why I am bullish on CVAC stock.
Why CureVac (CVAC) Stock Is Moving
Shares of CureVac BV (NASDAQ: CVAC) fell by 12.3% to $4.10 Wednesday afternoon. The pullback could be due to profit-taking after Tuesday's strong gains , which were fueled by heightened concerns over...
Vaccine makers’ shares jump after bird flu death in US
Moderna, Pfizer, CureVac and Novavax register gains as health agency stresses risk to public ‘remains low’
CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript
CureVac N.V. (NASDAQ:CVAC) Q3 2024 Earnings Conference Call November 12, 2024 9:00 AM ET Company Participants Sarah Fakih - Vice President of Corporate Communications and Investor Relations Alexander...
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter €400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increas...
CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based o...
CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
Experienced CFO and investment banker with 30-year track record will help drive CureVac's transformation TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (Nasdaq:CVAC) (...